{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:42:06Z","timestamp":1793968926625,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Italian Society of Obstetrics and Gynecology"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ygyno.2020.01.010","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T20:52:17Z","timestamp":1579035137000},"page":"209-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis"],"prefix":"10.1016","volume":"157","author":[{"given":"V.","family":"Ghirardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Moruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bizzarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Vargiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D'Indinosante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Garganese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pasciuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Loverro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.01.010_bb0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","article-title":"Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining \u2018optimal\u2019 residual disease","volume":"125","author":"Chang","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.01.010_bb0010","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.010_bb0015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1991.9.7.1138","article-title":"Long follow-up and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience","volume":"9","author":"Omura","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.01.010_bb0020","first-page":"1234","article-title":"Role of surgical outcome as prognostic factor randomized phase 3 multicenter trials","volume":"115","author":"Bois","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.010_bb0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2017.02.023","article-title":"Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?","volume":"145","author":"Sioulas","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.010_bb0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2018.08.014","article-title":"Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival?","volume":"151","author":"Tseng","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"9990","key":"10.1016\/j.ygyno.2020.01.010_bb0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ygyno.2020.01.010_bb0040","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2020.01.010_bb0045","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.01.010_bb0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-015-0439-z","article-title":"Radical surgery in ovarian cancer","volume":"17","author":"Narasimhulu","year":"2015","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2020.01.010_bb0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.01.010_bb0060","article-title":"Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: a meta-analysis of peri-operative outcome","volume":"12","author":"Yang","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ygyno.2020.01.010_bb0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ygyno.2019.02.019","article-title":"The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; a systematic review","volume":"153","author":"Timmermans","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.010_bb0070","doi-asserted-by":"crossref","first-page":"676.e1","DOI":"10.1016\/j.ajog.2007.10.495","article-title":"Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer","volume":"197","author":"Aletti","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.01.010_bb0075","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ygyno.2018.12.011","article-title":"Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy","volume":"152","author":"Davidson","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.01.010_bb0080","doi-asserted-by":"crossref","first-page":"642.e1","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.01.010_bb0090","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1245\/s10434-014-4141-4","article-title":"Development and assessment of memorial Sloan Kettering Cancer Center\u2019s surgical secondary events grading system","volume":"22","author":"Strong","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.010_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"FIGO committee on gynecologic oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"4","key":"10.1016\/j.ygyno.2020.01.010_bb0100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ygyno.2020.01.010_bb0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2020.01.010_bb0110","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer. Chem. Rep."},{"issue":"5","key":"10.1016\/j.ygyno.2020.01.010_bb0115","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1245\/s10434-015-5051-9","article-title":"What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer?","volume":"23","author":"Chiva","year":"2016","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.01.010_bb0120","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"Bois","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2020.01.010_bb0125","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/IGC.0000000000000690","article-title":"Minimal macroscopic residual disease (0.1-1 cm). Is it still a surgical goal in advanced ovarian cancer?","volume":"26","author":"Chiva","year":"2016","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2020.01.010_bb0130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ygyno.2015.03.049","article-title":"Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care","volume":"137","author":"G\u00f3mez-Hidalgo","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.010_bb0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2015.07.095","article-title":"Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept","volume":"139","author":"Petrillo","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.01.010_bb0140","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ygyno.2018.10.017","article-title":"Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer","volume":"151","author":"Hansen","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2020.01.010_bb0145","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"suppl","key":"10.1016\/j.ygyno.2020.01.010_bb0150","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Bois","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2020.01.010_bb0155","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.01.010_bb0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2478\/raon-2018-0030","article-title":"Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals","volume":"52","author":"Kobal","year":"2018","journal-title":"Radiol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.01.010_bb0165","doi-asserted-by":"crossref","first-page":"632.e1","DOI":"10.1016\/j.ajog.2014.06.034","article-title":"Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer","volume":"211","author":"Petrillo","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.01.010_bb0170","doi-asserted-by":"crossref","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","article-title":"BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","volume":"217","author":"Petrillo","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.ygyno.2020.01.010_bb0175","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1097\/IGC.0000000000001352","article-title":"Efficacy of neoadjuvant therapy with cisplatin plus mitomycin C in BRCA1-mutated ovarian cancer","volume":"28","author":"Gorodnova","year":"2018","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:48:59Z","timestamp":1758772139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820300172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0090825820300172"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}